Trial · NCT07059676
Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer
NCT07059676, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer. Trials, record NCT07059676. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07059676
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer
- NCT number
- NCT07059676
- Status
- Not yet recruiting
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Zejula (Niraparib)
- First posted
- 2025-07-11
- Last updated
- 2025-07-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Multiplex protein detection panel - Early progression | 0-24 months | To identify a multiplex protein detection panel based on protein and cytokine from plasma at baseline and at 4 and 12 weeks from baseline, associated with early progression, defined as progression in the first 6 months after initiation of niraparib maintenance. |
| Primary | Multiplex protein detection panel - Absence of progression | 0-24 months | To identify a multiplex protein detection panel based on protein and cytokine from plasma at baseline and at 4 and 12 weeks from baseline, associated with absence of progression at 18 months after initiation of niraparib maintenance |
| Secondary | Multiplex protein detection panel - Progression | 0-12 months | To identify a multiplex protein detection panel based on protein and cytokine from plasma at baseline and at 4 and 12 weeks from baseline, associated to progression in the first 12 months after initiation of niraparib maintenance. |
| Secondary | Multiplex protein detection panel - Absence of progression (12 + 24 months) | 0-24 months | To identify a multiplex protein detection panel based on protein and cytokine from plasma at baseline and at 4 and 12 weeks from baseline, associated to absence of progression at 12 and 24 months after initiation of niraparib maintenance |
| Secondary | Plasma protein identification - Progression | 0-12 months | To identify proteins in plasma at baseline and at 4 and 12 weeks from baseline, associated to progression in the first 6 and 12 months after initiation of niraparib maintenance. |
| Secondary | Plasma protein identification - Absence of progression | 0-24 months | To identify proteins in plasma at baseline and at 4 and 12 weeks from baseline, associated to absence of progression at 12, 18 and 24 months after initiation of niraparib maintenance. |
| Secondary | Plasma cytokines identification - Progression | 0-12 months | To identify cytokines in plasma at baseline and at 4 and 12 weeks from baseline, associated to progression in the first 6 and 12 months after initiation of niraparib maintenance. |
| Secondary | Plasma cytokines identification - Absence of progression | 0-24 months | 6\. To identify cytokines in plasma at baseline and at 4 and 12 weeks from baseline, associated to absence of progression at 12, 18 and 24 months after initiation of niraparib maintenance. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07059676
GET https://conductscience.org/api/trials/v1/NCT07059676/registered